Site Search      
Home About Us Technology Products Investors Clinical Trials Careers Contact Us
Products
GI-4000
GI-5005
Preclinical products
Intellectual Property
Publications
 
GlobeImmune’s Hepatitis C Product Candidate Improves End of Treatment Response in All IL-28 B Genotypes, with the Greatest Effect in the Hardest-to-Treat Patients

GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to be First Therapeutic Vaccine for HCV

GlobeImmune Announces Presentations of GI-5005 Phase 2b Data at EASL 2010 Meeting

Tarmogen Products
Copyright © GlobeImmune Inc. All Rights Reserved.
Developed by Mango Media Corporation